The estimated Net Worth of Lynn Dorsey Bleil is at least $853 Thousand dollars as of 25 May 2021. Ms. Bleil owns over 28,605 units of Amicus Therapeutics Inc stock worth over $566,994 and over the last 9 years she sold FOLD stock worth over $0. In addition, she makes $285,801 as Independent Director at Amicus Therapeutics Inc.
Lynn has made over 1 trades of the Amicus Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she bought 28,605 units of FOLD stock worth $250,008 on 25 May 2021.
The largest trade she's ever made was buying 28,605 units of Amicus Therapeutics Inc stock on 25 May 2021 worth over $250,008. On average, Lynn trades about 753 units every 0 days since 2015. As of 25 May 2021 she still owns at least 50,310 units of Amicus Therapeutics Inc stock.
You can see the complete history of Ms. Bleil stock trades at the bottom of the page.
Lynn Dorsey Bleil serves as Independent Director of the Company. Lynn D. Bleil has served as a member of the Board since September 2018. Ms. Bleil led the West Coast Healthcare Practice of McKinsey & Company and was a core leader of McKinsey’s worldwide Healthcare Practice before her retirement as a Senior Partner in 2013, after 25 years at the firm. Currently, Ms. Bleil serves as a member of the Board of Directors of Stericycle, Inc. (NASDAQ: SRCL), Sonova Holding AG (VX: SOON) and Alcon AG (NYSE:ALC). Her prior directorships included DST Systems, Inc. (NYSE: DST), and Auspex Pharmaceuticals (NASDAQ: ASPX). Ms. Bleil received her B.S.E. in Chemical Engineering from Princeton University and her M.B.A. from the Stanford Graduate School of Business.
As the Independent Director of Amicus Therapeutics Inc, the total compensation of Lynn Bleil at Amicus Therapeutics Inc is $285,801. There are 14 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.
Lynn Bleil is 57, she's been the Independent Director of Amicus Therapeutics Inc since 2018. There are 7 older and 12 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Lynn's mailing address filed with the SEC is 47 HULFISH STREET, , PRINCETON, NJ, 08542.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris, and Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: